Skip to content

Clinical evaluation of melasma (Jhaain) with Unani drug

Therapeutic Evaluation Of Topical BÄ?dÄ?m Talkh In Treatment Of Kalaf (Melasma): A Randomized Standard Control Trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/03/032310
Enrollment
40
Registered
2021-03-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma

Interventions

Intervention1: Badam Talkh (Prunus amygdalus amara): Zimad(Paste) of Badam Talkh (Prunus amygdalus amara)will be applied locally on the affected parts twice daily for 20 minutes Control Intervention1:

Sponsors

Luqman Unani Medical College Hospital and Research Center
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: -Clinically diagnosed patients of bilateral facial Kalaf and confirmed by dermoscope -Epidermal and mixed melasma based on dermoscope

Exclusion criteria

Exclusion criteria: -Already diagnose systematic and skin allergic diseases -Skin sensitivity 1-4 type by Fitzpatrick skin type -Pregnant and lactating women -Hypersensitivity reaction to Hydroquinone -Use of Hydroquinone and other anti-tyrosinase drugs within 3 months from baseline -History of chemical peels and facial laser treatment within 9 months and use of sun protector creams

Design outcomes

Primary

MeasureTime frame
Change in mMASI(Modified Melasma Area Severity Index)Timepoint: Baseline, 2nd week, 4th week, 6th week, 8th week

Secondary

MeasureTime frame
Change in Investigatorâ??s Global Assessment For Melasma Severity on 100mm VAS. Change in Patientâ??s Global Assessment (PtGA). Change in Dermatology Life Quality Index (DLQI)Timepoint: Baseline, 2nd week, 4th week, 6th week, 8th week

Countries

India

Contacts

Public ContactMohd Khalid

Luqman Unani Medical College,Hospital and Research Centre

drmqkhan@yahoo.com9849438319

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026